Featured Application: Inhibition of Tdp1 has the potential to increase the potency of the anticancer drugs topotecan and irinotecan, topoisomerase 1 poisons. Furthermore, Tdp1 inhibitors can facilitate the therapeutic use of these drugs in other cancer types.
Previously we synthesized a number of esters of 1-adamantane carboxylic acid containing fragments of acyclic, monocyclic and bicyclic monoterpenoids. A potent Tdp1 inhibitory activity Hz) and long-range spin-spin coupling constants (HMBC, 2,3 J 7 Hz) and 1 H -1 H double-resonance spectra (COSY, NOESY). Numeration of atoms in the compounds (see Supplementary Materials, Figures S7-S15) is given for assigning the signals in the NMR spectra and does not coincide with the nomenclature of the compounds. The elemental composition of compounds was determined from high-resolution mass spectra (HR-MS) recorded on a DFS Thermo Scientific spectrometer in full scan mode (0-500 m/z, 70 eV electron impact ionization, direct sample injection). The conversion of reagents, the content of the compounds in fractions during chromatography and the purity of the target compounds was determined using gas chromatography methods: 7820A gas chromatograph (Agilent Tech., USA), flame-ionization detector, HP-5 capillary column (0.25 mm × 3 m × 0.25 µm), helium carrier gas (flow rate 2 mL/min, flow division 99:1), temperature range from 120 to 280 • C, heating 20 • C/min. The purity of the target compounds for biological testing was confirmed to be more than 95%.
Synthesis of Amines 36, 37
Bromides 40, 41 were synthesized from 3,7-dimethyloctanol 38 and nerol 39 (1.0 g, 6.5 mmol, 2.5 eq) by stirring of with PBr 3 (0.24 mL, 2.6 mmol, 1 eq) in diethyl ether (38) and THF (39) solutions (10 mL of each solvents) at cooling according to the methods [42, 51] . Then, the derivatives 40, 41 obtained were used without further purification. To solution 40 and 41 (1.2 g, 5.4 mmol, 1 eq) in dry DMF (40 mL) potassium phthalimide (1.0 g, 5.4 mmol, 1 eq) was added, the reaction mixture was stirred at 50 • C until the reaction completed, treated with water (100 mL) and extracted by CHCl 3 . The extract was washed by 5% NaOH solution (50 mL), brine (50 mL) and evaporated with water and toluene consequentially. Resulted residues were purified by column chromatography with yielding phthalimides 42 (1.3 g, 4.5 mmol, yield 95%) and 43 (1.1 g, 4.0 mmol, yield 74%). To solution of 42 and 43 (1.1 g, 4.0 mmol, 1 eq) in methanol (30 mL), ethylenediamine (0.53 mL, 8.0 mmol, 2 eq) was added, the mixture was refluxed until the reaction completed, treated with water (30 mL) and extracted by Et 2 O. The organic layer was washed by 5% NaOH (30 mL), brine (30 mL) and dried under Na 2 SO 4 . The solvent was evaporated and hexane (30 mL) was added to the residue. The solution was filtered and the solvent was distilled off yielding 36 (0.34 g, 2.4 mmol, yield 55%) and 37 (0.57 g, 3.7 mmol, yield 94%).
General Procedure for Amides 44a,b; 45a,b; 50a,b
Citronellic acid (0.30 g, 1.7 mmol, 1 eq) was previously refluxed with thionyl chloride (0.25 mL, 3.5 mmol, 2 eq) in toluene (15 mL) 2 h. The solvent was distilled off and the citronellic acid chloride 48 was obtained (0.32 g, 1.7 mmol, yield 98%). To solution of carboxylic acid chlorides 31, 32 (0.16 g, 0.79 mmol, 1 eq), 48 (0.15 g, 0.79 mmol, 1 eq) in dry toluene (20 mL) amines 36, 37 (0.12 g, 0.79 mmol, 1 eq), as well as 1-and 2-aminoadamantanes 49a,b (0.12 g, 0.79 mmol, 1 eq) and trimethylamine (0.11 mL, 0.79 mmol, 1 eq) were added at 0 • C. The mixtures were stirred overnight at room temperature, evaporated, dissolved in EtOAc (30 mL), washed by 5% NaOH (20 mL), brine (20 mL) and dried with Na 2 SO 4 . The solvent was distilled off under reduced pressure and the solid obtained was purified by column chromatography yielding amides 44a,b; 45a,b; 50a,b.
N-(3,7-Dimethyloctyl)adamantane-1-carboxamide 44a
Yield 85%. 1 calc. 319.2870). 2.1.6. N-((Z)-3,7-Dimethylocta-2,6-dien-1-yl)adamantane-2-carboxamide 45b To the solution of amides 44a,b; 45a,b (53 mg, 0.16 mmol, 1 eq), 50b (50 mg, 0.16 mmol, 1 eq) in dry toluene (10 mL), Py (6.6 µL, 82 µmol, 0.5 eq) and Lawesson's reagent (0.20, 0.49 mmol, 3 eq) were added, the mixture was refluxed overnight in argon atmosphere [52] . The solvent was evaporated, the residue was dissolved in Et 2 O and washed with saturated solution of NaHCO 3 (20 mL) and brine (20 mL) consequentially and dried with Na 2 SO 4 . Thioamides were purified by column chromatography. Yield 31%. A NMR spectra of trans-and cis-isomers at C-14-C-15 bond was obtained for their mixture in ratio ≈ 1.0:0.8, respectively. In 1 H-NMR spectrum the signals of corresponding protons of isomers superimpose on each other. In 13 C-NMR spectrum, most of the carbon signals of both isomers differ. 1 
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Modelling and Screening
The compounds were docked against the crystal structure of Tdp1 PDB ID: 1MU7, resolution 2.0 Å) [53] which was obtained from the Protein Data Bank (PDB, Cambridge, UK) [54, 55] . The Scigress version FJ 2.6 program [56] was used to prepare the crystal structure for docking (i.e., the hydrogen atoms were added, the co-crystallised tungsten(VI)ion was removed as well as crystallographic water molecules). For further studies, HOH631 and HOH832 water molecules were kept in the crystal structure. The Scigress software suite was also used to build the inhibitors and the MM2 [57] force field was used to optimise the structures. The docking centre was defined as the position of the hydrogen atom of His263, whereby nitrogen formed a coordination bond with the tungsten ion (x = 7.319, y = 0.055, z = 96.688) with 10 Å radius. Fifty docking runs were allowed for each ligand with default search efficiency (100%). The basic amino acids lysine and arginine were defined as protonated.
Furthermore, aspartic and glutamic acids were assumed deprotonated. The GoldScore(GS) [58] and ChemScore(CS) [59, 60] , Piecewise Linear Potential (ChemPLP) [61] and Astex Statistical Potential (ASP) [62] scoring functions were implemented to validate the predicted binding modes and relative energies of the ligands using the GOLD v5.4.1 software suite. The QikProp 3.2 [63] software package was used to calculate the molecular descriptors of the molecules. The reliability of it is established for the calculated descriptors [64] .
Biological Study

TDP1 Activity
A fluorophore quencher-coupled DNA-biosensor for real-time measurement of Tdp1 cleavage activity was designed recently in our laboratory [29] . This biosensor is a short single-stranded oligonucleotide with a 5 -FAM fluorophore and a 3 -BHQ1 (black hole quencher 1) quencher.
Recombinant protein Tdp1 was expressed in Escherichia coli (pET 16B plasmid containing Tdp1 cDNA was provided by Dr. K.W. Caldecott, University of Sussex, United Kingdom) and isolated as described [7, 65] . The reaction mixture in a final volume 200 µL contained Tdp1 reaction buffer (50 mM Tris-HCl, 50 mM NaCl, 7 mM β-mercaptoethanol), 50 nM biosensor and varied concentrations of potential inhibitor. Purified Tdp1 was added in a final concentration of 1.5 nM.
The reaction mixtures were incubated at a temperature of 26 • C in a POLARstar OPTIMA fluorimeter, BMG LABTECH, GmbH, Germany, to measure fluorescence intensity every 1 min (Ex485/Em520 nm). Tdp1 inhibition was calculated by comparing the rate of increase in fluorescence of biosensor in the presence of compound to that of DMSO (1.5%) control wells. The measurements were carried out in at least two independent experiments. IC 50 values were determined using a six-point concentration response curve. The data were imported into MARS Data Analysis 2.0 program (BMG LABTECH) and the slope during the linear phase (here data from 0 to 7 min) was calculated.
Cytotoxicity Assay
Analysis of the toxicity of the compounds was examined against human cell line A-549 (adenocarcinomic human alveolar basal epithelial cells) using a standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) test [66] by colorimetric measurement of the amount of formazan converted from MTT in cells exposed to the compounds. The cell line was obtained from the Russian Cell Culture Collection (RCCC) Institute of Cytology RAS, St. Petersburg, Russia. The cells were grown in IMDM medium, with 40 µg/mL gentamicin, 50 IU/mL penicillin, 50 µg/mL streptomycin (MP Biomedicals, Solon, USA) and in the presence of 10% fetal bovine serum (Biolot, Saint Petersburg, Russia) in 5% CO 2 atmosphere. After formation of a 30-50% monolayer, tested compounds were added to the medium (the volume of added reagents was 1/100 of the total volume of the culture medium, the amount of DMSO was 1% of the final volume), and the cell culture was monitored for 3 days. Control cells were grown in the presence of 1% DMSO. The Tdp1 inhibitor concentrations ranged from 1 to 100 µM. Topotecan concentrations ranged from 30 to 3000 nM in the presence of 5 µM Tdp1 inhibitor or 1% DMSO. The measurements were carried out in three parallel experiments.
Binding Studies
Intrinsic protein fluorescence assay were conducted according to the protocol as described in references [35, 45, 49] . The concentrations of recombinant Tdp1 and ligand were 10 µM and 1 mM, respectively. Excitation wavelength was 280 nm and intrinsic fluorescence was measured between 300 and 450 nm.
Thermal shift assay was carried out using a modified protocol that was described in [67] . Experiments were carried out using an Applied BioSystems QuantStudio 3 Real-Time PCR system. Samples were measured using 96-well PCR plates (Bio-Rad). Reaction volume was 25 µL. Protein unfolding was monitored by measuring the fluorescence of the SYPRO Orange dye (Sigma Aldrich, St Louis, MO, US). Temperature was increased from 25 to 95 • C at 1 • C increments every 60 s. The final concentrations of Tdp1 and compounds were 20 and 100 µM, respectively. Buffer contained 20 mM Tris (pH 8.0), 250 mM NaCl and 2.5 × SYPRO Orange dye. Measurements were performed in triplicate. For determination of melting temperature values, melting curve for each data set was analysed by SigmaPlot 13 (USA) and fitted with the Sigmoid, 3-parameter model.
Results and Discussion
Organic Synthesis
To synthetize amides and thioamides, commercially available 1-adamantane carboxylic acid chloride 31 was used. An isomeric chloride of 2-adamantane carboxylic acid 32 was obtained starting from adamantan-2-one 33 according to previously published methods [68] [69] [70] including the synthesis of epoxide 34, its treatment with boron trifluoride etherate and subsequent oxidization (Scheme 1). 2-Adamantane carboxylic acid 35 was refluxed in thionyl chloride yielding chloride 32 quantitatively. Monoterpene amines 36 and 37 were obtained by Gabriel synthesis. Using this approach, bromides 40 and 41 were synthesized starting from 3,7-dimethyloctanol 38 and nerol 39, respectively [42, 51] . Then the bromides were stirred with potassium phthalimide at 60 • C giving compounds 42 and 43. Compounds 40 and 41 were purified by column chromatography. Their interaction with ethylenediamine led to amines 37 and 38. It was found that subsequent dissolving in hexane and precipitate filtration followed by solvent evaporation led to pure amines (Scheme 1).
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Inhibition Studies
The binding and inhibition potency of the compounds were tested against purified recombinant Tdp1. Binding experiments were conducted using thermal shift assay [71] and an intrinsic fluorescence binding assay that we previously developed [35, 45, 49] . Thermal shift assay measures the stability of proteins against thermal degradation. If a molecule binds to the protein, it may be stabilized or destabilized by the binding of the molecule, thus leading to a shift of the protein melting temperature. The intrinsic fluorescence binding assay measures the fluorescence intensity of tryptophan residues of a protein. The active site of Tdp1 is close to several tryptophan residues. Binding of Tdp1 inhibitors may change the environment of these tryptophan residues, thus leading to quenching of fluorescence intensity. However, no significant changes in the melting temperature of Tdp1 or quenching of Tdp1 fluorescence intensity were observed (Supplementary Figures S1-S6 ). This may be due to the low solubility of our compounds (1 mM or less) in aqueous buffer. As our binding assays typically required at least tens of µM of Tdp1, we reasoned that the lack of changes in melting temperature and intrinsic fluorescence intensity are likely due the low ligand-to-protein ratio needed in our experiments, which did not allow complete formation of Tdp1-inhibitor complex.
Therefore, the inhibition potency of our compounds 44a,b-47a,b; 50a,b; 51 were tested against Tdp1 by using a biosensor assay previously developed [29] . The biosensor is 16-mer single-stranded oligonucleotide containing a 5'-FAM (5(6)-carboxyfluorescein) fluorophore donor and a quenching 3'-BHQ1 (Black Hole Quencher-1). Because BHQ1 and FAM are located within the Förster radius, the fluorescence is quenched. The mechanism of action is based on the Tdp1 enzyme's ability to selectively cleave substituents from the 3'-end of DNA [72] , thus deriving the Tdp1 activity by real-time fluorescence detection [29, 32] . Table 1 shows the Tdp1 inhibition potency of the compounds 44a,b-47a,b; 50a,b; 51. Furamidine 11, a commercially-available Tdp1 inhibitor, was used as a positive control. Compounds 46b and 47b were not investigated in Tdp1 inhibitory activity tests due to their instability. The compounds synthesized can be divided in to two groups: (1) amides and thioamides of 1-and 2-adamantane carboxylic acids (44a,b; 45a,b; 46a; 47a); (2) derivatives of citronellic acid (50a,b; 51). Comparing inhibitory activity of the first group (Table 1) and compounds synthesized previously [49] it can be concluded that amides 44-47 are less active than their ester counterparts are. For example, in the cases of derivatives 29 (ester), 44 (amide), 48 (thioamide), which are structural analogues, the following IC 50 values were obtained: 0.92, >75 and 3.3 µM, respectively. Note that derivatives of 2-adamantane carboxylic acid were found to be more active compared to compounds obtained from 1-admantane carboxylic acid. Thus, amides 44a and 44b were not active, whilst 45a and 45b showed Tdp1 50% inhibition at 5.2 and 2.5 µM, respectively (Table 1) . Comparing amide 45a and thioamide 47a activity it can be concluded that, for 2-adamantane carboxylic acid derivatives, oxygen atom replacement by sulphur also led to activity increasing, with IC 50 being 5.2 µM for 45a and 0.64 µM for 47a. Similar trends were observed for citronellic acid derivatives 50a,b; 51. For example, 1-aminoadamnatane derivative 50a was not active whilst 2-aminoadamantane 50b activity was found to be slightly higher and the best IC 50 value was obtained for thioamide 51 (2.3 µM), also a 2-aminoadamantane derivative. In general, based on the results shown in Table 1 and previously published results [49] , the following conclusions can be made: (1) Thioamides are more active than the esters and they have better activity than their amide counterparts; (2) 2-adamanatne substituted derivatives (45a, 45b, 47a, 50b and 51) are more active compared to 1-adamantane substituted isomers (44a, 44b, 46a and 50a).
Cytotoxicity
The intrinsic cytotoxicity of the adamantane derivatives was examined using the lung adenocarcinoma A-549 cell line and the standard MTT assay, the results are shown in Figure S16 . In general, all the compounds were mildly toxic or non-cytotoxic: CC50 values (cytotoxic concentration at 50%) were >80 µM. Since Tdp1 inhibitors are supposed to be used for adjuvant therapy with established antitumor drugs, it is important that the Tdp1 therapeutic agents do not cause any side effects.
As already mentioned, the combined use of TOP1 poisons and Tdp1 inhibitors can lead to a synergistic effect. Topotecan is a bioavailable derivative of CPT, used in the clinic to treat, for example, lung cancer [73] . Despite the important role of topotecan in cancer therapy, resistance to CPTs and severe side effects are reported [73] . One of the ways to overcome resistance and/or reduce the dose of topotecan, and consequently its toxicity, is the joint use with Tdp1 inhibitors.
The cytotoxic effect of topotecan was studied in conjunction with the inhibitors. The adamantane derivatives were used in the nontoxic concentration of 5 µM. Most compounds had a In general, based on the results shown in Table 1 and previously published results [49] , the following conclusions can be made: (1) Thioamides are more active than the esters and they have better activity than their amide counterparts; (2) 2-adamanatne substituted derivatives (45a, 45b, 47a, 50b and 51) are more active compared to 1-adamantane substituted isomers (44a, 44b, 46a and 50a).
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As already mentioned, the combined use of TOP1 poisons and Tdp1 inhibitors can lead to a synergistic effect. Topotecan is a bioavailable derivative of CPT, used in the clinic to treat, for example, lung cancer [73] . Despite the important role of topotecan in cancer therapy, resistance to CPTs and severe side effects are reported [73] . One of the ways to overcome resistance and/or reduce the dose of topotecan, and consequently its toxicity, is the joint use with Tdp1 inhibitors. In general, based on the results shown in Table 1 and previously published results [49] , the following conclusions can be made: (1) Thioamides are more active than the esters and they have better activity than their amide counterparts; (2) 2-adamanatne substituted derivatives (45a, 45b, 47a, 50b and 51) are more active compared to 1-adamantane substituted isomers (44a, 44b, 46a and 50a).
The intrinsic cytotoxicity of the adamantane derivatives was examined using the lung adenocarcinoma A-549 cell line and the standard MTT assay, the results are shown in Figure S16 . In general, all the compounds were mildly toxic or non-cytotoxic: CC 50 values (cytotoxic concentration at 50%) were >80 µM. Since Tdp1 inhibitors are supposed to be used for adjuvant therapy with established antitumor drugs, it is important that the Tdp1 therapeutic agents do not cause any side effects.
The cytotoxic effect of topotecan was studied in conjunction with the inhibitors. The adamantane derivatives were used in the nontoxic concentration of 5 µM. Most compounds had a weak or no sensitizing effect (data not shown). The most pronounced was by compound 46a (Figure 3) , thioamide of 2-adamantane carboxylic acid with 3,7-dimethyloctane fragment. Therefore, 46a is the most promising derivative as it has high enough anti-Tdp1 activity, low cytotoxicity and synergism with topotecan.
Molecular Modeling
The eleven molecules were docked into the binding site of Tdp1 (PDB ID: 1MU7, resolution 2.0 Å) [53] with reasonable scores, as shown in Table S1 in the supplementary materials. Furthermore, two water molecules (H2O631 and H2O832) were kept in the binding pocket and all the ligands docked. The modelling shows that all the ligands show a similar plausible binding mode for both scenarios. The ligands have higher scores with water (see Table S1 ), which suggests that they contribute to the stability of the protein and binding. Indeed, the modelling predicts that the ligands interact with the water molecules. For the most interesting compound 46a, the sulphur atom forms an H-bond with HOH631, this water molecule also interacts with Thr261, forming an H-bond bridge between the ligand the protein. The second water molecule HOH832 does not form direct H-bonds with the ligand but nudges the adamantane moiety closer to a lipophilic region. The adamantane moiety occupies a relatively lipophilic portion of the binding pocket whilst the thioamide occupies a hydrophilic portion as shown with Figure 4A .
The calculated molecular descriptors molecular weight (MW), number of hydrogen bond donors (HDs), number of hydrogen bond acceptors (HAs), lipophilicity (Log P), polar surface area (PSA) and number of rotatable bonds (RBs) are given in Table S2 in the supplementary materials. HDs, HAs, and PSA are within the lead-like chemical space for all the ligands whilst the molecules have MW within the drug-like chemical space. The molecules are within the drug-like and known drug space (KDS) for Log P. The RBs are within the drug-like chemical space (for the definition of lead-like, drug-like and KDS regions see [54] and Table S3 ). Interestingly, it has been shown recently that orally bioavailable drugs tend not to follow the drug-like definition, in particular when it comes to MW [74] . The molecular weight of the ligands is between 303.5 and 335.6 g mol -1 and the Log P values lie in the range of 4.4 and 6.3. The ligands have low PSA values between 13.3 and 33.9. The known drug indexes 2a and 2b (KDIs2a/2b) [75] were also derived. The KDIs reflect the overall balance of the molecular properties of ligands based on KDS. KDI2a is additive with a maximum of 6.0 and for KDI2b the indexes are multiplied giving 1.0 as its maximum. The average for KDI2a for known drugs is 4.08 (±1.27) and the ligands lie in the range of 4.58 to 5.23 (i.e., they are well balanced Therefore, 46a is the most promising derivative as it has high enough anti-Tdp1 activity, low cytotoxicity and synergism with topotecan.
The calculated molecular descriptors molecular weight (MW), number of hydrogen bond donors (HDs), number of hydrogen bond acceptors (HAs), lipophilicity (Log P), polar surface area (PSA) and number of rotatable bonds (RBs) are given in Table S2 in the supplementary materials. HDs, HAs, and PSA are within the lead-like chemical space for all the ligands whilst the molecules have MW within the drug-like chemical space. The molecules are within the drug-like and known drug space (KDS) for Log P. The RBs are within the drug-like chemical space (for the definition of lead-like, drug-like and KDS regions see [54] and Table S3 ). Interestingly, it has been shown recently that orally bioavailable drugs tend not to follow the drug-like definition, in particular when it comes to MW [74] . The molecular weight of the ligands is between 303.5 and 335.6 g mol -1 and the Log P values lie in the range of 4.4 and 6.3. The ligands have low PSA values between 13.3 and 33.9. The known drug indexes 2a and 2b (KDIs 2a/2b ) [75] were also derived. The KDIs reflect the overall balance of the molecular properties of ligands based on KDS. KDI 2a is additive with a maximum of 6.0 and for KDI 2b the indexes are multiplied giving 1.0 as its maximum. The average for KDI 2a for known drugs is 4.08 (±1.27) and the ligands lie in the range of 4.58 to 5.23 (i.e., they are well balanced compared to known drugs). The KDI 2b gives a range of 0.18 to 0.43 with the average of know drugs being 0.18 (±0.20). The relatively low values can be attributed to the high Log Ps of 46a and 47a. The KDI 2b index is less forgiving, since on one low number sinks the index significantly due to its multiplicative nature. Nevertheless, the ligands are relatively well balanced. 
Conclusions
Previously, a family of esters functionalised with monoterpene and adamantine moieties was found to be good inhibitors of Tdp1. Esters are known to be labile (i.e., hydrolyse relatively easily at physiological conditions, rendering compounds containing esters potentially problematic as drug candidates). We; therefore, substituted the ester bridge with amide and thioamide groups and tested them against Tdp1. Derivative 46a stood out as the most promising candidate as it synergised with topotecan, a Top1 poison in clinical use against cancer, only at 5 µM, which is a fully non-toxic dose. The reported IC50 value is 3.3 µM, which is not the lowest of the series synthesised, but interestingly on 46a showed synergy with topotecan in the cancer cell line used (A-549 lung adenocarcinoma. According to molecular modelling, a good fit is predicted for 46a into the substrate pocket of Tdp1, inhibiting its activity.
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1 : Results of the scoring function for the ligands with and without two water molecules present; Table S2 : The calculated molecular descriptors for the ligands; Table S3 : Definition of lead-like, drug-like and known drug space (KDS) in terms of molecular descriptors. The values given are the maxima for each descriptor for the volumes of chemical space used; Figure S1 : Intrinsic fluorescence spectroscopy of Tdp1 in the presence of compounds 45, 45a 46a, 47a and 51. Samples contained 10 µM Tdp1 and 1 mM compound (if applicable) dissolved in a buffer containing 20 mM Tris (pH 8.0) and 250 mM NaCl. Control experiments were conducted with DMSO, which is the solvent that the compounds were dissolved in. Excitation wavelength was 280 nm and intrinsic fluorescence was measured between 300 and 450 nm. Maximum fluorescence intensity was reported. Other compounds were not tested because they are not soluble at the required concentration in aqueous buffer; Figure S2 : Protein melt curves showing the denaturing temperature of Tdp1 (10 µM, red) and Tdp1 (10 µM) in the presence of compound 44b (100 µM, blue) as monitored by thermal shift assay. Buffer was 20 mM Tris (pH 8.0) and 250 mM NaCl. Changes in denaturing temperature were found to be −0.27 °C; Figure S3 : Protein melt curves showing the denaturing temperature of Tdp1 (10 µM, red) and Tdp1 (10 µM) in the presence of compound 45a (100 µM, blue) as monitored by thermal shift assay. Buffer was 20 mM Tris (pH 8.0) and 250 mM NaCl. Changes in denaturing temperature were found to be 0.04 °C; Figure S4 : Protein melt curves showing the denaturing temperature of Tdp1 (10 µM, red) and Tdp1 (10 µM) in the presence of compound 46a (100 µM, blue) as monitored by thermal shift assay. Buffer was 20 mM Tris (pH 8.0) and 250 mM NaCl. Changes in denaturing 
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